Latest News & Features
article
We are delighted to have Justice Birss join our editor-in-chief, Peter Scott, to discuss the UK patent landscape and revisit some of the key judgements of the past few years, and well as to get thoughts on the future of IP in the UK post-Brexit and beyond. 24 September 2020
Americas
Danish biotech Genmab has commenced binding arbitration of two matters with Janssen Biotech, a Johnson & Johnson company, over royalty payments for a cancer drug. 24 September 2020
Americas
ERS Genomics, the company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, has appointed Michael Arciero as vice-president of IP and commercial development. 23 September 2020
Americas
Canada-based Bausch Health has dropped its litigation against Indian generic maker Sun Pharma as part of a settlement agreement. 23 September 2020
Americas
Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago. 23 September 2020
Americas
Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid. 22 September 2020
Americas
Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer. 22 September 2020
Biotechnology
The Federal Court of Australia has rejected Boehringer Ingelheim’s animal health unit's attempt to stop the registration of a patent owned by Intervet International on various grounds. 21 September 2020
Americas
Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard. 21 September 2020
Biotechnology
In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court. 21 September 2020